NCT05024175 Long-term Follow-up of Subjects Treated With CAR T Cells
| NCT ID | NCT05024175 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marcela V. Maus, M.D.,Ph.D. |
| Condition | Long Term Adverse Effects |
| Study Type | OBSERVATIONAL |
| Enrollment | 45 participants |
| Start Date | 2023-08-07 |
| Primary Completion | 2038-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 45 participants in total. It began in 2023-08-07 with a primary completion date of 2038-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).
Eligibility Criteria
Inclusion Criteria: Subjects will be asked to participate leading up to the last DF/HCC corresponding main study visit. Subjects meeting the following criteria are eligible for study participation: * Provision of voluntary written informed consent by subject * CAR T cells were administered in DF/HCC IRB corresponding main study Exclusion Criteria: Subjects meeting the following criterion are to be excluded from study participation: \- Subject unable to comply with study requirements
Contact & Investigator
Matthew J Frigault, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT05024175 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Long Term Adverse Effects. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05024175 currently recruiting?
Yes, NCT05024175 is actively recruiting participants. Contact the research team at mfrigault@mgb.org for enrollment information.
Where is the NCT05024175 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05024175 clinical trial?
NCT05024175 is sponsored by Marcela V. Maus, M.D.,Ph.D.. The principal investigator is Matthew J Frigault, MD at Massachusetts General Hospital. The trial plans to enroll 45 participants.